Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Interest & Investment Income (2024 - 2026)

Maze Therapeutics' Interest & Investment Income history spans 3 years, with the latest figure at $3.2 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 22.79% to $3.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.4 million, a 77.09% increase, with the full-year FY2025 number at $11.8 million, up 153.09% from a year prior.
  • Interest & Investment Income hit $3.2 million in Q1 2026 for Maze Therapeutics, down from $3.5 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for MAZE hit a ceiling of $3.5 million in Q4 2025 and a floor of $281000.0 in Q1 2024.
  • Historically, Interest & Investment Income has averaged $2.2 million across 3 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 830.6% in 2025 and later increased 22.79% in 2026.
  • Tracing MAZE's Interest & Investment Income over 3 years: stood at $1.5 million in 2024, then surged by 130.28% to $3.5 million in 2025, then decreased by 8.02% to $3.2 million in 2026.
  • Business Quant data shows Interest & Investment Income for MAZE at $3.2 million in Q1 2026, $3.5 million in Q4 2025, and $2.9 million in Q3 2025.